|Blood & Marrow April 2019 Vol 3.4
In this issue:
Of all the fields of medicine perhaps Clinical Hematology is the one which has seen most
phenomenal changes in last two decades. From
introduction of Tyrosine Kinase Inhibitors in 2001 to
Chimeric Antigen Receptor (CAR) T Cells couple of years
ago, there is unprecedented introduction of game
changing treatments one after another. Patients with
hopeless diseases are now being offered cure. But all
this has come with a price, especially for resource
constrained countries like Pakistan.
Many of the newer drugs are either not registered and
not available or they are so expensive that very few
patients can afford them. So far, there appears to be no
concerted effort to take on the challenge of rapidly
evolving pharmacopeia of hematological diseases.
Reaching out for biosimilars and developing the
technology to locally produce newer drugs and biological
agents is the need of the hour.
Till next time. Its,